ClinicalTrials.gg
RecruitingNCT06808633Updated Feb 25, 2025

Efficacy of Direct Selective Laser Trabeculoplasty in Clinical Practice in Patients with Glaucoma

An observational study in Glaucoma, sponsored by Clínica Rementería. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Clínica Rementería · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Glaucoma with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Glaucoma · Spain.

Planned enrollment
10th of 10
30 · median 365
Started
2025
with 1 other
Observational
10 of 43
3 open now
Registered
41st of 43
by date
Lead sponsor
2 of 43
Clínica Rementería

Among the 43 studies in Glaucoma with a site in Spain, this one is the 10th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2025, is one of 10 observational ones, and was the 41st registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 43 studies in Glaucoma with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Glaucoma with a site in Spain, or all of them as a file.
02

Study summary

Prospective, single-arm, single-center, non-randomized, non-comparative study including naïve patients attending our center diagnosed with glaucoma, who have been recommended treatment with direct selective laser trabeculoplasty (DSLT) by their ophthalmologist and who are under no hypotensive medication. DSLT treatment will be performed with the Voyager DSLT system; it will consist of the application of 120 laser pulses of preset 3 ns and a preset 400 μm spot size, with an energy of 1.8 mJ delivered to the limbus through a full 360 degrees.

The study will evaluate the effect of DSLT on intraocular pressure (IOP). Baseline IOP will be the IOP measured with Goldman applanation tonometry by the investigator on the day of treatment, prior to the application of DSLT. Patients will be seen one week (±2 days), one month (±7 days), three months (±15 days), six months (±30 days) and 12 months (±40 days) after DSLT treatment. In each of these visits, the attending ophthalmologist will measure IOP with Goldmann applanation tonometry and record the presence of any relevant ocular signs and query patients regarding potential adverse events. The study´s main end-point will be percentage reduction in IOP six months after DSLT compared to baseline.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • direct selective laser trabeculoplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with open angle glaucoma in study eye and scheduled for both eyes being treated after bilateral laser indication.

Eligibility criteria

Inclusion Criteria: • Age over 18 years

  • Diagnosis of open angle glaucoma in eye study and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value>21 mmHg.

Exclusion Criteria:

  • Patients diagnosed with uveitis, angle closure or congenital glaucoma.
  • Presence of anterior peripheral synechiae
  • Patients unable to complete three, six- and 12-months follow-up.
  • Patients having undergone intraocular surgery, save for uneventful phacoemulsification (performed at least 6 months prior to inclusion)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study participants

    Age over 18 years Diagnosis of open angle glaucoma instudy eye and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value\>21 mmHg.

06

What researchers measure

Primary outcomes

  1. Percentage change in IOP six months after DSLT compared to baseline.

    Percentage change in IOP six months after DSLT compared to baseline.

    Time frame: 6 months after DLST application

Secondary outcomes

  1. Percentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.

    Percentage change in washed-out IOP 3 and 12 months after DSLT compared to baseline.

    Time frame: 12 months

  2. Mean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.

    Mean washed-out IOP change 3, 6 and 12 months after DSLT compared to baseline.

    Time frame: 12 months

  3. Proportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.

    Proportion of participants with at least 20% reduction in washed-out IOP from baseline at 3, 6 and 12 months.

    Time frame: 12 months

  4. Percentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months

    Percentage of patients using hypotensive topical treatment after DSLT at 3, 6, and 12 months

    Time frame: 12 months

  5. Mean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).

    Mean number of medications 3, 6 and 12 months after DSLT (accounting for those on no medications as well when calculating the average).

    Time frame: 12 months

Other outcomes

  1. Glaucoma Quality of Life-15 Questionnaire at 12 months after DSLT.

    Glaucoma Quality of Life-15 Questionnaire at 12 months after DSLT. It consists of 15 questions asking about patients difficulty for performing everyday tasks, which the patient must grade from 1 to 5, with 1 being that patient has no difficulty performing the task and 5 that he has severe diificulties. Values range from 15 (no difficulties for any activity) to 45 (has severe difficulties for performing all activities)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Age, gender, baseline IOP, severity of glaucoma, IOP at each follow-up visit, need for glaucoma medications

Supporting information: Clinical study report

Time frame: At the end of study (expected winter 2026) and for five years

Access criteria: Data deposited in a dataset repository, accessed by identified researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Sep 2026, 18 months later.

Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 18 months is below that.

Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2025
First posted
Feb 5, 2025
StartEst.
Mar 1, 2025
Primary completionEst.
Sep 20, 2026
CompletionEst.
Sep 20, 2026
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06808633
Lead sponsor
Clínica Rementería
Responsible party
Sponsor
First posted
Feb 5, 2025
Start date
Mar 1, 2025 (estimated)
Primary completion
Sep 20, 2026 (estimated)
Completion
Sep 20, 2026 (estimated)
Last update
Feb 25, 2025

Study contacts

Inés Contreras
Contact
contreras@clinicarementeria.es
+34913083838

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion